The European Commission has approved a new oral anticoagulant; apixaban.
Numerous trials were conducted to test the new drug against warfarin, aspirin, dabigatran and rivaroxaban. Apixaban was found to be effective at reducing major bleeding and AF-related stroke.
The drug has been approved for patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as aged 75 years or over, hypertension, diabetes, prior stroke or transient ischemic attack (TIA) or symptomatic heart failure.
Moreover, unlike warfarin, new oral anticoagulants (apixaban, dabigatran and rivaroxaban) do not require international normalised ratio (INR) monitoring. The trials did not demonstrate any known dietary restrictions either.
The drug is being considered for approval in the USA.